M2 macrophages secrete glutamate-containing extracellular vesicles to alleviate osteoporosis by reshaping osteoclast precursor fate

Mol Ther. 2024 Apr 3;32(4):1158-1177. doi: 10.1016/j.ymthe.2024.02.005. Epub 2024 Feb 7.

Abstract

Osteoclast precursors (OCPs) are thought to commit to osteoclast differentiation, which is accelerated by aging-related chronic inflammation, thereby leading to osteoporosis. However, whether the fate of OCPs can be reshaped to transition into other cell lineages is unknown. Here, we showed that M2 macrophage-derived extracellular vesicles (M2-EVs) could reprogram OCPs to downregulate osteoclast-specific gene expression and convert OCPs to M2 macrophage-like lineage cells, which reshaped the fate of OCPs by delivering the molecular metabolite glutamate. Upon delivery of glutamate, glutamine metabolism in OCPs was markedly enhanced, resulting in the increased production of α-ketoglutarate (αKG), which participates in Jmjd3-dependent epigenetic reprogramming, causing M2-like macrophage differentiation. Thus, we revealed a novel transformation of OCPs into M2-like macrophages via M2-EVs-initiated metabolic reprogramming and epigenetic modification. Our findings suggest that M2-EVs can reestablish the balance between osteoclasts and M2 macrophages, alleviate the symptoms of bone loss, and constitute a new approach for bone-targeted therapy to treat osteoporosis.

Keywords: extracellular vesicles; macrophage; metabolic-epigenetic reprogramming; osteoclast; osteoporosis.

MeSH terms

  • Extracellular Vesicles*
  • Glutamic Acid / metabolism
  • Humans
  • Macrophages / metabolism
  • Osteoclasts / metabolism
  • Osteoporosis* / genetics
  • Osteoporosis* / metabolism
  • Osteoporosis* / therapy

Substances

  • Glutamic Acid